

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-72. (canceled)

73. (Currently Amended) An amphiphilic drug-oligomer conjugate comprising a therapeutic compound comprising an enkephalin compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled to a hydrophilic moiety, and wherein the oligomer has the formula:



wherein

$m = 1$  to  $6$ ;

$n = 0$  or  $1$ ;

$x = 0, 3$  or  $6$ ;

$y = 1, 2, 3$  or  $6$ ;

$z = 2, 3, 7$  or  $8$ ;

$\text{A} = \text{single bond, CO or CONHCH}_2\text{CH}_2$ ; and

$\text{E} = \text{OH or OCH}_2\text{COOH}$ .

74. (Canceled).

75. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the amphiphilic drug-oligomer conjugate exhibits the biological activity of the therapeutic compound without cleavage of the therapeutic compound from the oligomer.

76. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the amphiphilic drug-oligomer conjugate does not exhibit the biological activity of the therapeutic compound without cleavage of the therapeutic compound from the oligomer.

77. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the

lipophilic moiety is coupled to the hydrophilic moiety by a hydrolyzable bond.

78. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the lipophilic moiety is coupled to the hydrophilic moiety by a non-hydrolyzable bond.

79. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the lipophilic moiety is coupled to the hydrophilic moiety by a bond selected from the group consisting of: amide bond, carbamate bond, carbonate bond and ester bond.

80. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the oligomer is coupled to the therapeutic compound by a bond selected from the group consisting of amide bond, carbamate bond, carbonate bond and ester bond.

81. (Currently Amended) The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic compound is a peptide having enkephalin compound comprises~~ an added N-terminal residue selected from the group consisting of proline and alanine.

82. (Canceled).

83. (Currently Amended) The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic compound is an enkephalin compound is met-enkephalin-lys (SEQ ID NO:1) or an analog thereof.~~

84. (Currently Amended). The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic enkephalin~~ compound is met<sup>5</sup>-enkephalin (SEQ ID NO:48) or an analog thereof.

85. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the therapeutic compound is met-enkephalin-lys (SEQ ID NO:1) and the oligomer has the formula:



wherein m = 1, n = 0, A = CONHCH<sub>2</sub>CH<sub>2</sub>, E = OH, x = 0, y = 6, and z = 2.

86. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the therapeutic compound is met-enkephalin-lys (**SEQ ID NO:1**) and the oligomer has the formula:



wherein m = 1, n = 0, A = CONHCH<sub>2</sub>CH<sub>2</sub>, E = OH, x = 3, y = 2, and z = 7.